Pathologists face challenges when distinguishing peritoneal mesothelioma from peritoneal carcinomatosis. Both conditions can appear similar under the microscope. Accurate diagnosis remains essential for proper treatment planning. Immunohistochemical and molecular biomarker analysis helps resolve this difficulty. Immunohistochemistry forms the first line of investigation. Pathologists apply a panel of antibodies to tissue samples. Mesothelial markers such as […]
KRAS-Targeted Drugs: From Molecular Discovery to Clinical Application Introduction KRAS is one of the most important oncogenic drivers in human cancer. It belongs to the RAS family of small GTPases. These proteins regulate cell growth, survival and proliferation. For decades, KRAS was considered difficult to target with drugs. Scientists struggled to find suitable binding sites […]
Analysis of Immune Checkpoint Inhibitor Efficacy in Mesothelioma Immune checkpoint inhibitors have changed treatment approaches for several cancers. Researchers now examine their effectiveness in mesothelioma. Studies stratify results by PD-L1 expression and histological subtype. This analysis helps identify which patients benefit most. PD-L1 expression serves as a key biomarker. Higher PD-L1 levels often correlate with […]
In this article we will discuss Cytoreductive Surgery and HIPEC in Peritoneal Malignancies
In this article we will discuss Oncogenic Signaling Pathways: PI3K/AKT/mTOR
In this article we will discuss Analytical and clinical validation of liquid biopsy assays for minimal residual disease detection after curative treatment